Brief: Strides Pharma Science Gets U.S. FDA Approval For Ibuprofen Otc Oral Suspension
10/06/2022 10:35
June 10 (Reuters) - Strides Pharma Science Ltd SRID.NS :
* SAYS GETS US FDA APPROVAL FOR IBUPROFEN OTC ORAL
SUSPENSION
Source text - https://bit.ly/3MxSbgk
Further company coverage: SRID.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Strides Pharma Science
See all newsIndia's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Brief: Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Brief: Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Brief: Strides Pharma Science March-Quarter Consol Net Profit 1.27 Billion Rupees